H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes

Judes G., Dagdemir A., Karsli-Ceppioglu S., Lebert A., Echegut M., Ngollo M., ...Daha Fazla

Epigenomics, cilt.8, sa.7, ss.909-924, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8 Sayı: 7
  • Basım Tarihi: 2016
  • Doi Numarası: 10.2217/epi-2016-0015
  • Dergi Adı: Epigenomics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.909-924
  • Anahtar Kelimeler: breast cancer, H3 modifications, St Gallen molecular subtypes, INTERNATIONAL EXPERT CONSENSUS, HISTONE MODIFICATIONS, DNA HYPERMETHYLATION, DEVELOPMENTAL GENES, CANCER HIGHLIGHTS, BRCA1 EXPRESSION, PRIMARY THERAPY, ESTROGEN, ASSOCIATION, HER-2/NEU
  • Marmara Üniversitesi Adresli: Evet

Özet

Aim: Here, we investigated how the St Gallen breast molecular subtypes displayed distinct histone H3 profiles. Patients & methods: 192 breast tumors divided into five St Gallen molecular subtypes (luminal A, luminal B HER2-, luminal B HER2+, HER2+ and basal-like) were evaluated for their histone H3 modifications on gene promoters. Results: ANOVA analysis allowed to identify specific H3 signatures according to three groups of genes: hormonal receptor genes (ERS1, ERS2, PGR), genes modifying histones (EZH2, P300, SRC3) and tumor suppressor gene (BRCA1). A similar profile inside high-risk cancers (luminal B [HER2+], HER2+ and basal-like) compared with low-risk cancers including luminal A and luminal B (HER2-) were demonstrated. Conclusion: The H3 modifications might contribute to clarify the differences between breast cancer subtypes.